EUVIMEDEUVIMED entdecken
Multizentrische StudieStudienprotokollOpen Access · CC BY 4.0

Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT)

Sara Samadzadeh, Rafl Adnan, Paulina Berglova, Mahdi Barzegar, Birgit Debrabant, Stine Gundtoft Roikjaer, Michael Levy, Axel Petzold, Jacqueline Palace, Eoin P Flanagan, Sara Mariotto, Soeren T Skou und 16 weitere

Frontiers in Immunology · 2024

DOI: 10.3389/fimmu.2024.1380025 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Frontiers in Immunology, 2024. Verfasst von Sara Samadzadeh und 27 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Regional Health Research and, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Multiple Sclerosis, Comorbidity, Neuromyelitis Optica. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Comorbidities in patients with multiple sclerosis (MS) and antibody-mediated diseases of the central nervous system (CNS) including neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease (MOGAD) are common and may influence the course of their neurological disease. Comorbidity may contribute to neuronal injury and therefore limit recovery from attacks, accelerate disease progression, and increase disability. This study aims to explore the impact of comorbidity, particularly vascular comorbidity, and related risk factors on clinical and paraclinical parameters of MS, NMOSD and MOGAD. We propose COMMIT, a prospective multicenter study with longitudinal follow-up of patients with MS, NMOSD, and MOGAD, with or without comorbidities, as well as healthy subjects as controls. Subjects will be stratified by age, sex and ethnicity. In consecutive samples we will analyze levels of inflammation and neurodegeneration markers in both fluid and cellular compartments of the peripheral blood and cerebrospinal fluid (CSF) using multiple state-of-the-art technologies, including untargeted proteomics and targeted ultrasensitive ELISA assays and quantitative reverse transcription polymerase chain reaction (RT-qPCR) as well as high-dimensional single-cell technologies i.e., mass cytometry and single-cell RNA sequencing. Algorithm-based data analyses will be used to unravel the relationship between these markers, optical coherence tomography (OCT) and magnetic resonance imaging (MRI), and clinical outcomes including frequency and severity of relapses, long-term disability, and quality of life. The goal is to evaluate the impact of comorbidities on MS, NMOSD, and MOGAD which may lead to development of treatment approaches to improve outcomes of inflammatory demyelinating diseases of the CNS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisComorbidityNeuromyelitis OpticaHumansProspective StudiesMaleFemaleMyelin-Oligodendrocyte GlycoproteinAdultBiomarkersAutoantibodiesMiddle Aged

Stichwörter der Autor:innen

antibody-mediated diseases of the central nervous systemcomorbiditymultiple sclerosismyelin oligodendrocyte glycoprotein antibody-associated diseaseneuromyelitis optica spectrum disorder

Substanzen

Myelin-Oligodendrocyte GlycoproteinBiomarkersAutoantibodies

Autor:innen und Institutionen

  • Institute of Regional Health Research and, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • The Center for Neurological Research, Department of Neurology Slagelse Hospital, Slagelse, Denmark.
  • Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Berlin, Germany.
  • Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Department of Mathematics and Computer Science, Faculty of Natural Sciences, University of Southern Denmark, Odense, Denmark.
  • The Research and Implementation Unit PROgrez, Department of Physiotherapy and Occupational Therapy, Næstved-Slagelse-Ringsted Hospitals, Slagelse, Region Zealand, Denmark.

Zitieren

APA

Samadzadeh, S., Adnan, R., Berglova, P., Barzegar, M., Debrabant, B., Roikjaer, S. G., Levy, M., Petzold, A., Palace, J., Flanagan, E. P., Mariotto, S., Skou, S. T., Froelich, A., Lotan, I., Messina, S., Geraldes, R., Asseyer, S., Stiebel-Kalish, H., Oertel, F. C., …, & Asgari, N. (2024). Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT). Frontiers in Immunology. https://doi.org/10.3389/fimmu.2024.1380025

Vancouver

Samadzadeh S, Adnan R, Berglova P, Barzegar M, Debrabant B, Roikjaer SG, et al. Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT). Frontiers in Immunology. 2024. doi:10.3389/fimmu.2024.1380025

BibTeX
@article{Samadzadeh2024,
  author = {Samadzadeh, Sara and Adnan, Rafl and Berglova, Paulina and Barzegar, Mahdi and Debrabant, Birgit and Roikjaer, Stine Gundtoft and Levy, Michael and Petzold, Axel and Palace, Jacqueline and Flanagan, Eoin P and Mariotto, Sara and Skou, Soeren T and Froelich, Anne and Lotan, Itay and Messina, Silvia and Geraldes, Ruth and Asseyer, Susanna and Stiebel-Kalish, Hadas and Oertel, Frederike Cosima and Shaygannejad, Vahid and Sahraian, Mohammad Ali and Kim, Ho Jin and Bennett, Jeffrey L and Böttcher, Chotima and Zimmermann, Hanna G and Weinshenker, Brian G and Paul, Friedemann and Asgari, Nasrin},
  title = {Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT)},
  journal = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1380025}
}
Kostenlos starten →